<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2018.8933</article-id>
<article-id pub-id-type="publisher-id">mmr-18-01-0025</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of combined chondroitinase ABC and hyperbaric oxygen therapy in a rat model of spinal cord injury</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaoyang</given-names></name>
<xref rid="af1-mmr-18-01-0025" ref-type="aff"/>
<xref rid="c1-mmr-18-01-0025" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jiefeng</given-names></name>
<xref rid="af1-mmr-18-01-0025" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Guangkuo</given-names></name>
<xref rid="af1-mmr-18-01-0025" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Lv</surname><given-names>Honglin</given-names></name>
<xref rid="af1-mmr-18-01-0025" ref-type="aff"/></contrib>
</contrib-group>
<aff id="af1-mmr-18-01-0025">Department of Spine Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-18-01-0025"><italic>Correspondence to</italic>: Dr Xiaoyang Liu, Department of Spine Surgery, Yantai Yuhuangding Hospital, 20 Huang Ding Dong Road, Yantai, Zhifu, Shandong 264000, P.R. China, E-mail: <email>kx4464@163.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>07</month><year>2018</year></pub-date>
<pub-date pub-type="epub"><day>26</day><month>04</month><year>2018</year></pub-date>
<volume>18</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>30</lpage>
<history>
<date date-type="received"><day>23</day><month>07</month><year>2017</year></date>
<date date-type="accepted"><day>10</day><month>11</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Liu et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>The present study aimed to investigate the effect of combined hyperbaric oxygen (HBO) and chondroitinase ABC (ChABC) enzyme therapy in a rat model of spinal cord injury (SCI) and to explore the underlying mechanisms. A total of 48 healthy male Wistar rats were randomly divided into six groups: Sham, SCI, vehicle, HBO, ChABC enzyme and HBO &#x002B; ChABC. Excluding the sham group, SCI was established in rats by a clip compression injury and rats subsequently received HBO treatment for 2 weeks with or without an intraspinal injection of 0.1 U/&#x00B5;l ChABC. Neuromotor functions were examined using the Basso-Beattie-Bresnahan locomotor rating scale and the inclined plane assessment at baseline and for 4 weeks following SCI establishment. Superoxide dismutase (SOD) and malondialdehyde (MDA) levels were also measured, in addition to the expression of glycogen synthase kinase-3&#x03B2; (GSK3&#x03B2;) and aquaporin 4 (AQP4). Results revealed that combined HBO and ChABC treatment significantly improved neuromotor function compared with the HBO or ChABC treatments alone. HBO and/or ChABC treatment significantly increased SOD and decreased MDA levels, as well as GSK3&#x03B2; expression, compared with the sham and SCI rats. The combined HBO and ChABC treatment significantly inhibited SCI-induced AQP4 expression, but ChABC alone did not. Functional recovery in the HBO &#x002B; ChABC group was significantly increased compared with the HBO or ChABC groups. These results indicate that combined HBO and ChABC treatment is more effective in treating SCI than either therapy alone.</p>
</abstract>
<kwd-group>
<kwd>hyperbaric oxygen</kwd>
<kwd>glycogen synthase kinase-3&#x03B2;</kwd>
<kwd>chondroitinase ABC</kwd>
<kwd>superoxide dismutase</kwd>
<kwd>spinal cord injury</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Spinal cord injury (SCI) often leads to paralysis, has a high morbidity rate and occurs in both genders equally (<xref rid="b1-mmr-18-01-0025" ref-type="bibr">1</xref>,<xref rid="b2-mmr-18-01-0025" ref-type="bibr">2</xref>). A series of pathophysiological responses lead to progressive spinal cord tissue degeneration and necrosis following SCI. It is thought this is due to microcirculation disorder and neuronal biochemical imbalances involving prostaglandins, calcium, neurotransmitters and free radicals (<xref rid="b3-mmr-18-01-0025" ref-type="bibr">3</xref>). Despite numerous advances in medical science, no definitive treatment for SCI has been developed. Ongoing research aiming to resolve this issue has proposed various treatment options including medicinal, cell and gene therapies (<xref rid="b4-mmr-18-01-0025" ref-type="bibr">4</xref>&#x2013;<xref rid="b6-mmr-18-01-0025" ref-type="bibr">6</xref>). The lack of success observed in this research may be attributed to the complicated pathophysiology of SCIs and associated factors. For example, the inhibiting factor chondroitin sulfate proteoglycan (CSPG) is associated with glial scars and is thought to limit the effectiveness of SCI treatment (<xref rid="b7-mmr-18-01-0025" ref-type="bibr">7</xref>,<xref rid="b8-mmr-18-01-0025" ref-type="bibr">8</xref>).</p>
<p>It has been proposed that the primary factors influencing the outcome of patients with SCI are glial scarring and chronic inflammation (<xref rid="b9-mmr-18-01-0025" ref-type="bibr">9</xref>,<xref rid="b10-mmr-18-01-0025" ref-type="bibr">10</xref>). CSPG is an extracellular matrix molecule that is expressed following SCI and reaches its maximal expression two weeks following injury (<xref rid="b11-mmr-18-01-0025" ref-type="bibr">11</xref>). CSPG activates a cascade that leads to the activation of glycogen synthase kinase-3&#x03B2; (GSK3&#x03B2;), a key factor in the inhibition of tissue and axon recovery in the central nervous system (<xref rid="b12-mmr-18-01-0025" ref-type="bibr">12</xref>). Chondroitinase ABC (ChABC) is an enzyme produced by the bacteria <italic>Proteus vulgaris</italic> that cleaves disaccharides and tetrasaccharides (<xref rid="b13-mmr-18-01-0025" ref-type="bibr">13</xref>). It was demonstrated that the digestion of glycosaminoglycan (GAG) by ChABC may enhance axonal regeneration and improve neuromotor function following SCI (<xref rid="b14-mmr-18-01-0025" ref-type="bibr">14</xref>,<xref rid="b15-mmr-18-01-0025" ref-type="bibr">15</xref>). A loss of GAG occurs in intervertebral disc degeneration and thus, the injection of ChABC may be used to construct a model of this condition (<xref rid="b16-mmr-18-01-0025" ref-type="bibr">16</xref>). ChABC administration following SCI has moderate efficacy and its effectiveness may be improved by the simultaneous administration of other medications (<xref rid="b17-mmr-18-01-0025" ref-type="bibr">17</xref>&#x2013;<xref rid="b20-mmr-18-01-0025" ref-type="bibr">20</xref>).</p>
<p>Previous studies have demonstrated that lipid oxidation by free radicals has important implications in the outcome of SCI (<xref rid="b3-mmr-18-01-0025" ref-type="bibr">3</xref>,<xref rid="b21-mmr-18-01-0025" ref-type="bibr">21</xref>). Certain reports suggest that hyperbaric oxygen (HBO) treatment induces GAG synthesis, which reduces oxygen free radical generation in the body and subsequently reduces lipid oxidation and promotes SCI repair. However, other studies have concluded the opposite (<xref rid="b16-mmr-18-01-0025" ref-type="bibr">16</xref>,<xref rid="b22-mmr-18-01-0025" ref-type="bibr">22</xref>&#x2013;<xref rid="b24-mmr-18-01-0025" ref-type="bibr">24</xref>). Therefore, the effect of HBO on nerve injury is not fully understood. A previous study demonstrated that HBO may protect Sprague-Dawley rats induced by ChABC treatment from intervertebral disc degeneration (<xref rid="b16-mmr-18-01-0025" ref-type="bibr">16</xref>). However, less is known about the combined effect of HBO and ChABC therapy in a rat model of SCI. In the present study, the efficacy of simultaneous HBO and ChABC treatment in rats following SCI was examined. Serum malondialdehyde (MDA) and superoxide dismutase (SOD) levels were examined to evaluate the extent of lipid peroxidation in injured cells (<xref rid="b21-mmr-18-01-0025" ref-type="bibr">21</xref>).</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Experimental animals</title>
<p>The Ethics Committee of the Yantai Yuhuangding Hospital (Yantai, China) approved the protocol of animal care and handling in the present study. A total of 48 healthy male Wistar rats (150&#x2013;170 g) were provided by The Experimental Animal Center of Shandong University (Jinan, China). Rats had free access to food and water and were housed together in a 12 h light/dark cycle at 25&#x00B0;C and 75&#x0025; relative humidity, in specific pathogen-free conditions. Rats were randomly divided into six groups (<xref rid="tI-mmr-18-01-0025" ref-type="table">Table I</xref>).</p>
</sec>
<sec>
<title>Experimental SCI model</title>
<p>The experimental SCI model was induced in rats using the clip compression method (<xref rid="b18-mmr-18-01-0025" ref-type="bibr">18</xref>,<xref rid="b25-mmr-18-01-0025" ref-type="bibr">25</xref>). Rats were anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and xylasine (10 mg/kg). The laminectomy was performed at the T13-L1 level following skin and muscle incision. The spinal cord was compressed by a microvascular clip (Fine Science Tools GmbH, Heidelberg, Germany) that induced 20 g/cm<sup>2</sup> pressure for 90 sec. Animals were monitored for 4 weeks following surgery.</p>
</sec>
<sec>
<title>HBO treatment</title>
<p>HBO treatment began 2 h following SCI establishment and was continued once daily for 14 days. A medical hyperbaric oxygen chamber (Ningbo Hyperbaric Oxygen Corporation, Ningbo, China) was prepared with a flush of pure oxygen for 10 min. SCI-HBO rats were placed into the HBO chamber and exposed to 80&#x0025; oxygen at 0.3 MPa (3 ATA) for 60 min, followed by depressurization for 30 min. Control animals were treated with regular air.</p>
</sec>
<sec>
<title>ChABC injection</title>
<p>The injury site was re-exposed in anesthetized rats 7 days following surgery and ChABC (0.1 U/&#x00B5;l; total, 10 &#x00B5;l; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) diluted in 0.01&#x0025; bovine serum albumin (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and PBS was slowly intraspinally injected over 2 min using a 30 &#x00B5;m glass micropipette connected to a Hamilton syringe (depth, 1 mm), 2 mm rostral to injury site (<xref rid="b18-mmr-18-01-0025" ref-type="bibr">18</xref>). The needle was kept in the injection site for 1 min following the termination of the injection to prevent backflow.</p>
</sec>
<sec>
<title>Neuromotor function assessment</title>
<p>The Basso-Beattie-Bresnahan (BBB) locomotor rating scale (<xref rid="b26-mmr-18-01-0025" ref-type="bibr">26</xref>) and the inclined plane assessment were used to examine neuromotor function prior to surgery and for 4 weeks thereafter (<xref rid="b26-mmr-18-01-0025" ref-type="bibr">26</xref>). For the inclined plane assessment, the inclination angle of the board is freely adjustable. The maximum inclination angle of the board on which the rat stayed for 5 sec without falling off was recorded (<xref rid="b27-mmr-18-01-0025" ref-type="bibr">27</xref>). The BBB rating scale has a range of 0&#x2013;21 points, judged by parameters including the coordination of limb movement, paw placement and tail balance. No visible movement of the hind legs was scored as zero points. For the maximum 21 points, the rat had to walk continuously on its paws, with a cocked tail, good fore and hind limb motor coordination and trunk stability. Data was quantified as the average score of the two hind limbs.</p>
</sec>
<sec>
<title>SOD and MDA assays</title>
<p>Tail blood (1.5 ml) was obtained at 0, 2 and 4 weeks following SCI. SOD activity was measured using the xanthine oxidase assay (cat no. A001-1-1; Nanjing Jiancheng Bioengineering Institute, Nanjing, China) and MDA levels were detected using the thiobarbituric acid assay (cat no. A003-4; Nanjing Jiancheng Bioengineering Institute), according to the manufacturer&#x0027;s protocols.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Following the removal of the dura, spinal cord (100&#x2013;300 &#x00B5;g) from the T13-L1 level was homogenized on ice in radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China). Protein concentration was measured with a Nano dropper (Thermo Fisher Scientific, Inc.). The proteins (25 &#x00B5;g/lane) were electrophoresed on 10&#x0025; SDS-PAGE gel for 1 h at 120 V and subsequently transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). The blots were blocked with 5&#x0025; non-fat dry milk for 1 h at 37&#x00B0;C prior to incubation with the primary antibodies rabbit polyclonal anti-aquaporin 4 (AQP4; 1:100; catalog no. ab46182; Abcam, Cambridge, UK) and rabbit polyclonal anti-GSK3&#x03B2; (1:100; catalog no. ab15314, Abcam) overnight at 4&#x00B0;C. Following incubation with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:1,000; cat no. A0208; Beyotime Institute of Biotechnology) for 1 h at 37&#x00B0;C, the protein bands were visualized using the chemiluminescence substrate kit (Beyotime Institute of Biotechnology). GAPDH (1:2,000; cat no. sc-69778; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was used as an internal control. Densitometry analysis performed using the Image J software version 1.3 (National Institutes of Health, Bethesda, MD, USA).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>All data is presented as the mean &#x00B1; standard error. Statistical analyses were performed with SPSS software 15.0 (SPSS, Inc., Chicago, IL, USA). Data were analyzed using the two-sided repeated measures analysis of variance with the Bonferroni post-hoc test. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Hind limb neuromotor function assessment</title>
<p>The BBB locomotor rating scale and the inclined plane assessment were used to assess the hind limb neuromotor function, which is an important index for SCI (<xref rid="b26-mmr-18-01-0025" ref-type="bibr">26</xref>). Prior to establishment of the SCI, rats in all groups had a baseline BBB score of 21 points. Following SCI, the BBB score was significantly decreased in all groups compared with the control rats (P&#x003C;0.0001), indicating that motor functions were reduced following SCI. During the 4 week follow up, a certain degree of motor function recovery was observed, however the baseline level was not recovered. Sham rats had a BBB score of 21 throughout the study (<xref rid="f1-mmr-18-01-0025" ref-type="fig">Fig. 1</xref>).</p>
<p>The BBB score in the combination therapy group (HBO &#x002B; enzyme group) was significantly increased compared with the SCI rats 1 week following SCI establishment (P&#x003C;0.001). At week 2, 3 and 4, the BBB score was increased in the HBO, enzyme and HBO &#x002B; enzyme groups compared with the SCI group (P&#x003C;0.001). The BBB score increase in the HBO &#x002B; enzyme group was significantly greater compared with the HBO and enzyme groups at week 2 (P&#x003C;0.001), 3 (P&#x003C;0.001) and 4 (P&#x003C;0.001).</p>
<p>For the inclined plane assessment, rats in all groups achieved a maximum angle of ~63&#x00B0; prior to SCI establishment. The maximum inclination angles were significantly reduced and subsequently increased at 2, 3 and 4 weeks in all groups following SCI (P&#x003C;0.01). The maximum angle in the HBO &#x002B; enzyme, HBO and enzyme groups were significantly increased compared with the SCI group (P&#x003C;0.01). The angle in the HBO &#x002B; enzyme group was significantly increased compared with the HBO and enzyme groups (P&#x003C;0.05; <xref rid="f2-mmr-18-01-0025" ref-type="fig">Fig. 2</xref>). Therefore, the combination of HBO and ChABC significantly improved the motor function recovery following SCI compared with HBO or ChABC treatment alone.</p>
</sec>
<sec>
<title>Serum SOD and MDA content</title>
<p>To detect alterations in the generation of oxygen free radicals, serum SOD and MDA levels were detected. Following SCI, serum SOD levels were significantly decreased and serum MDA levels were significantly increased compared with the sham group. Serum SOD activity in HBO &#x002B; enzyme, HBO and enzyme groups were significantly increased compared with sham and SCI rats 2 weeks following SCI (<xref rid="f3-mmr-18-01-0025" ref-type="fig">Fig. 3A</xref>). Conversely, MDA levels were significantly decreased in the HBO &#x002B; enzyme, HBO and enzyme groups compared with the sham and SCI groups (<xref rid="f3-mmr-18-01-0025" ref-type="fig">Fig. 3B</xref>). SOD and MDA levels in HBO &#x002B; enzyme group were respectively increased or decreased compared with HBO and enzyme groups 2 and 4 weeks following SCI establishment. There was no significant alteration in SOD or MDA levels in the HBO and enzyme groups at 2 or 4 weeks.</p>
</sec>
<sec>
<title>GSK3&#x03B2; expression in the spinal cord</title>
<p>GSK3&#x03B2; is involved in the prevention of axon regeneration following SCI (<xref rid="b19-mmr-18-01-0025" ref-type="bibr">19</xref>,<xref rid="b28-mmr-18-01-0025" ref-type="bibr">28</xref>). Western blot analysis indicated that GSK3&#x03B2; expression was significantly upregulated compared with baseline following SCI establishment (P&#x003C;0.001) 4 weeks post-surgery. HBO (P&#x003C;0.01), enzyme (P&#x003C;0.01) and HBO &#x002B; enzyme (P&#x003C;0.001) treatments all significantly inhibited GSK3&#x03B2; expression. The combination of HBO and ChABC reduced GSK3&#x03B2; expression to sham rat expression levels, indicating that this combination may be effective in improving the outcome of SCI (<xref rid="f4-mmr-18-01-0025" ref-type="fig">Fig. 4</xref>).</p>
</sec>
<sec>
<title>Assessment of AQP4 expression in the spinal cord</title>
<p>Increased AQP4 expression impedes SCI recovery (<xref rid="b29-mmr-18-01-0025" ref-type="bibr">29</xref>,<xref rid="b30-mmr-18-01-0025" ref-type="bibr">30</xref>). Western blot analysis determined that AQP4 expression was significantly increased compared with the sham group following SCI establishment (P&#x003C;0.001). HBO (P&#x003C;0.01) and HBO &#x002B; enzyme (P&#x003C;0.001) treatment significantly inhibited the expression of AQP4 compared with the SCI group. The enzyme treatment alone did not significantly inhibit the expression of AQP4 compared with the SCI group. The strongest inhibition of AQP4 expression was observed in the HBO &#x002B; enzyme treatment group (<xref rid="f5-mmr-18-01-0025" ref-type="fig">Fig. 5</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In the present study, the therapeutic effects of HBO and ChABC administrated alone and in combination in SCI rats was examined. The combination of HBO and ChABC was demonstrated to have the most beneficial effects on BBB scores, motor function recovery and the expression of SOD, MDA, GSK3&#x03B2; and AQP4, compared with the administration of either treatment alone.</p>
<p>Lipid peroxidation and the extent of neuronal damage may be assessed by the detection of inflammatory mediators, including SOD and MDA (<xref rid="b21-mmr-18-01-0025" ref-type="bibr">21</xref>). SOD is a naturally occurring neuroprotective free radical scavenger that converts harmful superoxide radicals into hydrogen peroxide. MDA is a key product of membrane lipid peroxidation, which is involved in the mitochondrial respiratory chain complex and exacerbates damage to the membrane. In the present study, HBO treatment significantly improved neuromotor function compared with the sham and SCI rats, suggesting an increase in SOD activity and reduced lipid peroxidation by oxygen free radicals. This indicates that oxygen free radical inhibition may be one of the mechanisms by which HBO treatment improves neuromotor function in SCI rats.</p>
<p>There are two primary obstacles that impede recovery following SCI: The expression of inflammatory factors and the production of CSPG (<xref rid="b31-mmr-18-01-0025" ref-type="bibr">31</xref>). A direct correlation exists between the production of inflammatory cytokines and CSGP (<xref rid="b31-mmr-18-01-0025" ref-type="bibr">31</xref>). In SCI, CSGP is involved in processes of cell death, demyelination, cavitation, microglial invasion and eventually the impairment of neuromotor function (<xref rid="b14-mmr-18-01-0025" ref-type="bibr">14</xref>,<xref rid="b15-mmr-18-01-0025" ref-type="bibr">15</xref>). Inflammation is associated with an increase in GSK3&#x03B2; expression in SCI (<xref rid="b28-mmr-18-01-0025" ref-type="bibr">28</xref>,<xref rid="b32-mmr-18-01-0025" ref-type="bibr">32</xref>). GSK3&#x03B2; is involved in the induction of demyelination and Wallerian degeneration (<xref rid="b12-mmr-18-01-0025" ref-type="bibr">12</xref>,<xref rid="b28-mmr-18-01-0025" ref-type="bibr">28</xref>). GSK3&#x03B2; also regulates the production of CSGP and thus prevents axonal regeneration following SCI (<xref rid="b19-mmr-18-01-0025" ref-type="bibr">19</xref>,<xref rid="b28-mmr-18-01-0025" ref-type="bibr">28</xref>). Increased CSGP expression may also contribute to neuromotor function impairment through the disruption of axonal connections and axonal regeneration (<xref rid="b28-mmr-18-01-0025" ref-type="bibr">28</xref>). All these mechanisms may be involved in the BBB decrease observed in SCI rats and the recovery of neuromotor function following HBO &#x002B; enzyme treatment in the present study. ChABC enzyme administration may directly overcome the endothelial barrier through the degradation of CSPG (<xref rid="b33-mmr-18-01-0025" ref-type="bibr">33</xref>), thus creating a permeable environment that allows axonal regeneration (<xref rid="b34-mmr-18-01-0025" ref-type="bibr">34</xref>,<xref rid="b35-mmr-18-01-0025" ref-type="bibr">35</xref>). A previous study indicated that enzyme secretion begins within a day of injury and reaches its maximum expression following 1 week (<xref rid="b11-mmr-18-01-0025" ref-type="bibr">11</xref>). Therefore, the enzyme was injected 1 week following SCI establishment. ChABC may exhibit anti-inflammatory properties (<xref rid="b36-mmr-18-01-0025" ref-type="bibr">36</xref>). The results of the current study revealed that GSK3&#x03B2; expression decreased in the combined treatment and that neuromotor function following SCI was improved, which is indicative of reduced demyelination and axonal regeneration (<xref rid="b32-mmr-18-01-0025" ref-type="bibr">32</xref>,<xref rid="b37-mmr-18-01-0025" ref-type="bibr">37</xref>). The combined HBO and ChABC treatment may have created a permeable environment by decreasing CSPG and GSK3&#x03B2; to promote neuromotor function.</p>
<p>Previous studies have demonstrated that local edema occurs immediately following SCI, due to endothelial barrier permeability injury (<xref rid="b38-mmr-18-01-0025" ref-type="bibr">38</xref>,<xref rid="b39-mmr-18-01-0025" ref-type="bibr">39</xref>). Microglial invasion and inflammatory cytokine production increases, leading to cell death, demyelination, cavity formation, paralysis and even mortality (<xref rid="b40-mmr-18-01-0025" ref-type="bibr">40</xref>,<xref rid="b41-mmr-18-01-0025" ref-type="bibr">41</xref>). AQP4 may reduce edema by facilitating the excretion of excessive water (<xref rid="b42-mmr-18-01-0025" ref-type="bibr">42</xref>). However, increased AQP4 expression in the chronic stage of SCI may be indicative of continued water retention and cytotoxic edema that impedes recovery (<xref rid="b29-mmr-18-01-0025" ref-type="bibr">29</xref>,<xref rid="b30-mmr-18-01-0025" ref-type="bibr">30</xref>). A previous study suggested that the role of HBO in the dysregulation of blood-brain barrier permeability should be taken into consideration when patients are exposed to HBO (<xref rid="b43-mmr-18-01-0025" ref-type="bibr">43</xref>). Additionally, Wang <italic>et al</italic> (<xref rid="b16-mmr-18-01-0025" ref-type="bibr">16</xref>) reported that HBO therapy significantly suppresses the decrease in disc height caused by ChABC injection, suggesting that HBO may protect the intervertebral discs against ChABC-induced injury. Consistent with these results, the present study demonstrated that combined HBO and ChABC therapy exerted a protective effect in the SCI rat model. Although alterations in the permeability of the spinal cord vasculature were not directly detected, to the best of the author&#x0027;s knowledge, the present study is the first to demonstrate the combined effect of ChABC and HBO in SCI. It was revealed that the expression of AQP4 in SCI rats was not significantly decreased by ChABC alone, indicating cytotoxic edema may be a limitation for this treatment. Results also indicated that HBO may protect against permeability barrier destruction by ChABC, however this conclusion should be validated with further research. The association of HBO with ChABC is still unclear and further investigation of the molecular mechanisms and associated signaling pathways are required.</p>
<p>In conclusion, the results of the present study demonstrated that although the application of HBO and ChABC alone reduced the GSK3&#x03B2; level and improved neuromotor recovery in SCI model rats, ChABC alone did not inhibit the induction of AQP4 expression following SCI, which may be a limitation to this treatment. In the combined treatment group, the expression of GSK3&#x03B2; and AQP4 was returned to baseline and the recovery of neuromotor function was improved. Increased serum SOD activity and decreased serum MDA content indicated a potential role of oxygen free radicals in the pathophysiological consequences of SCI. These alterations were reversed by the combined HBO and ChABC treatment. Therefore, the combined treatment was concluded to be more effective than application of either treatment alone. Improved neuromotor function was likely due to a reduction in inflammation by ChABC and HBO, as well as the degradation of CSPG by ChABC which contributes to the preservation of tissue integrity. Future studies should aim to further understand the underlying mechanisms.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-mmr-18-01-0025"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>A</given-names></name></person-group><article-title>Spinal-cord injury: Neural interfaces take another step forward</article-title><source>Nature</source><volume>539</volume><fpage>177</fpage><lpage>178</lpage><year>2016</year><pub-id pub-id-type="doi">10.1038/539177a</pub-id><pub-id pub-id-type="pmid">27830789</pub-id></element-citation></ref>
<ref id="b2-mmr-18-01-0025"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ropper</surname><given-names>AE</given-names></name><name><surname>Ropper</surname><given-names>AH</given-names></name></person-group><article-title>Acute spinal cord compression</article-title><source>N Engl J Med</source><volume>376</volume><fpage>1358</fpage><lpage>1369</lpage><year>2017</year><pub-id pub-id-type="doi">10.1056/NEJMra1516539</pub-id><pub-id pub-id-type="pmid">28379788</pub-id></element-citation></ref>
<ref id="b3-mmr-18-01-0025"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>ED</given-names></name></person-group><article-title>Lipid antioxidants in acute central nervous system injury</article-title><source>Ann Emerg Med</source><volume>22</volume><fpage>1022</fpage><lpage>1027</lpage><year>1993</year><pub-id pub-id-type="doi">10.1016/S0196-0644(05)82018-9</pub-id><pub-id pub-id-type="pmid">8503522</pub-id></element-citation></ref>
<ref id="b4-mmr-18-01-0025"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajiboye</surname><given-names>AB</given-names></name><name><surname>Willett</surname><given-names>FR</given-names></name><name><surname>Young</surname><given-names>DR</given-names></name><name><surname>Memberg</surname><given-names>WD</given-names></name><name><surname>Murphy</surname><given-names>BA</given-names></name><name><surname>Miller</surname><given-names>JP</given-names></name><name><surname>Walter</surname><given-names>BL</given-names></name><name><surname>Sweet</surname><given-names>JA</given-names></name><name><surname>Hoyen</surname><given-names>HA</given-names></name><name><surname>Keith</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Restoration of reaching and grasping movements through brain-controlled muscle stimulation in a person with tetraplegia: A proof-of-concept demonstration</article-title><source>Lancet</source><volume>389</volume><fpage>1821</fpage><lpage>1830</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/S0140-6736(17)30601-3</pub-id><pub-id pub-id-type="pmid">28363483</pub-id><pub-id pub-id-type="pmcid">5516547</pub-id></element-citation></ref>
<ref id="b5-mmr-18-01-0025"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capogrosso</surname><given-names>M</given-names></name><name><surname>Milekovic</surname><given-names>T</given-names></name><name><surname>Borton</surname><given-names>D</given-names></name><name><surname>Wagner</surname><given-names>F</given-names></name><name><surname>Moraud</surname><given-names>EM</given-names></name><name><surname>Mignardot</surname><given-names>JB</given-names></name><name><surname>Buse</surname><given-names>N</given-names></name><name><surname>Gandar</surname><given-names>J</given-names></name><name><surname>Barraud</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>D</given-names></name><etal/></person-group><article-title>A brain-spine interface alleviating gait deficits after spinal cord injury in primates</article-title><source>Nature</source><volume>539</volume><fpage>284</fpage><lpage>288</lpage><year>2016</year><pub-id pub-id-type="doi">10.1038/nature20118</pub-id><pub-id pub-id-type="pmid">27830790</pub-id><pub-id pub-id-type="pmcid">5108412</pub-id></element-citation></ref>
<ref id="b6-mmr-18-01-0025"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebedev</surname><given-names>MA</given-names></name><name><surname>Nicolelis</surname><given-names>MA</given-names></name></person-group><article-title>Brain-machine interfaces: From basic science to neuroprostheses and neurorehabilitation</article-title><source>Physiol Rev</source><volume>97</volume><fpage>767</fpage><lpage>837</lpage><year>2017</year><pub-id pub-id-type="doi">10.1152/physrev.00027.2016</pub-id><pub-id pub-id-type="pmid">28275048</pub-id></element-citation></ref>
<ref id="b7-mmr-18-01-0025"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagherzadeh</surname><given-names>K</given-names></name><name><surname>Maleki</surname><given-names>M</given-names></name><name><surname>Golestani</surname><given-names>A</given-names></name><name><surname>Khajeh</surname><given-names>K</given-names></name><name><surname>Amanlou</surname><given-names>M</given-names></name></person-group><article-title>Chondrotinase ABC I thermal stability is enhanced by site-directed mutagenesis: A molecular dynamic simulations approach</article-title><source>J Biomol Struct Dyn</source><fpage>1</fpage><lpage>10</lpage><year>2017</year></element-citation></ref>
<ref id="b8-mmr-18-01-0025"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauvala</surname><given-names>H</given-names></name><name><surname>Paveliev</surname><given-names>M</given-names></name><name><surname>Kuja-Panula</surname><given-names>J</given-names></name><name><surname>Kulesskaya</surname><given-names>N</given-names></name></person-group><article-title>Inhibition and enhancement of neural regeneration by chondroitin sulfate proteoglycans</article-title><source>Neural Regen Res</source><volume>12</volume><fpage>687</fpage><lpage>691</lpage><year>2017</year><pub-id pub-id-type="doi">10.4103/1673-5374.206630</pub-id><pub-id pub-id-type="pmid">28616017</pub-id><pub-id pub-id-type="pmcid">5461598</pub-id></element-citation></ref>
<ref id="b9-mmr-18-01-0025"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>YM</given-names></name><name><surname>He</surname><given-names>C</given-names></name></person-group><article-title>The glial scar in spinal cord injury and repair</article-title><source>Neurosci Bull</source><volume>29</volume><fpage>421</fpage><lpage>435</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s12264-013-1358-3</pub-id><pub-id pub-id-type="pmid">23861090</pub-id><pub-id pub-id-type="pmcid">5561940</pub-id></element-citation></ref>
<ref id="b10-mmr-18-01-0025"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramoto</surname><given-names>A</given-names></name><name><surname>Imagama</surname><given-names>S</given-names></name><name><surname>Natori</surname><given-names>T</given-names></name><name><surname>Wakao</surname><given-names>N</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Tauchi</surname><given-names>R</given-names></name><name><surname>Hirano</surname><given-names>K</given-names></name><name><surname>Shinjo</surname><given-names>R</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>N</given-names></name><name><surname>Kadomatsu</surname><given-names>K</given-names></name></person-group><article-title>Midkine overcomes neurite outgrowth inhibition of chondroitin sulfate proteoglycan without glial activation and promotes functional recovery after spinal cord injury</article-title><source>Neurosci Lett</source><volume>550</volume><fpage>150</fpage><lpage>155</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.neulet.2013.06.025</pub-id><pub-id pub-id-type="pmid">23811026</pub-id></element-citation></ref>
<ref id="b11-mmr-18-01-0025"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>LL</given-names></name><name><surname>Margolis</surname><given-names>RU</given-names></name><name><surname>Tuszynski</surname><given-names>MH</given-names></name></person-group><article-title>The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury</article-title><source>Exp Neurol</source><volume>182</volume><fpage>399</fpage><lpage>411</lpage><year>2003</year><pub-id pub-id-type="doi">10.1016/S0014-4886(03)00087-6</pub-id><pub-id pub-id-type="pmid">12895450</pub-id></element-citation></ref>
<ref id="b12-mmr-18-01-0025"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dill</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS</article-title><source>J Neurosci</source><volume>28</volume><fpage>8914</fpage><lpage>8928</lpage><year>2008</year><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1178-08.2008</pub-id><pub-id pub-id-type="pmid">18768685</pub-id></element-citation></ref>
<ref id="b13-mmr-18-01-0025"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbari</surname><given-names>M</given-names></name><name><surname>Khaksari</surname><given-names>M</given-names></name><name><surname>Rezaeezadeh-Roukerd</surname><given-names>M</given-names></name><name><surname>Mirzaee</surname><given-names>M</given-names></name><name><surname>Nazari-Robati</surname><given-names>M</given-names></name></person-group><article-title>Effect of chondroitinase ABC on inflammatory and oxidative response following spinal cord injury</article-title><source>Iran J Basic Med Sci</source><volume>20</volume><fpage>806</fpage><lpage>812</lpage><year>2017</year><pub-id pub-id-type="pmid">28852446</pub-id><pub-id pub-id-type="pmcid">5569595</pub-id></element-citation></ref>
<ref id="b14-mmr-18-01-0025"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>CT</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Tsai</surname><given-names>MJ</given-names></name><name><surname>Huang</surname><given-names>WH</given-names></name><name><surname>Huang</surname><given-names>MC</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Huang</surname><given-names>WC</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name></person-group><article-title>Local delivery of high-dose chondroitinase ABC in the sub-acute stage promotes axonal outgrowth and functional recovery after complete spinal cord transection</article-title><source>PLoS One</source><volume>10</volume><fpage>e0138705</fpage><year>2015</year><pub-id pub-id-type="doi">10.1371/journal.pone.0138705</pub-id><pub-id pub-id-type="pmid">26393921</pub-id><pub-id pub-id-type="pmcid">4579094</pub-id></element-citation></ref>
<ref id="b15-mmr-18-01-0025"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>JB</given-names></name><name><surname>Muir</surname><given-names>D</given-names></name></person-group><article-title>Chondroitinase C selectively degrades chondroitin sulfate glycosaminoglycans that inhibit axonal growth within the endoneurium of peripheral nerve</article-title><source>PLoS One</source><volume>11</volume><fpage>e0167682</fpage><year>2016</year><pub-id pub-id-type="doi">10.1371/journal.pone.0167682</pub-id><pub-id pub-id-type="pmid">27973564</pub-id><pub-id pub-id-type="pmcid">5156433</pub-id></element-citation></ref>
<ref id="b16-mmr-18-01-0025"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>IC</given-names></name><name><surname>Liu</surname><given-names>HT</given-names></name><name><surname>Yu</surname><given-names>CM</given-names></name><name><surname>Whu</surname><given-names>SW</given-names></name><name><surname>Lin</surname><given-names>SS</given-names></name><name><surname>Su</surname><given-names>CI</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>WJ</given-names></name></person-group><article-title>Effect of hyperbaric oxygenation on intervertebral disc degeneration: An in vivo study with sprague-dawley rats</article-title><source>Spine (Phila Pa 1976)</source><volume>38</volume><fpage>E137</fpage><lpage>E142</lpage><year>2013</year><pub-id pub-id-type="doi">10.1097/BRS.0b013e31827bf6bf</pub-id><pub-id pub-id-type="pmid">23138406</pub-id></element-citation></ref>
<ref id="b17-mmr-18-01-0025"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alluin</surname><given-names>O</given-names></name><name><surname>Delivet-Mongrain</surname><given-names>H</given-names></name><name><surname>Gauthier</surname><given-names>MK</given-names></name><name><surname>Fehlings</surname><given-names>MG</given-names></name><name><surname>Rossignol</surname><given-names>S</given-names></name><name><surname>Karimi-Abdolrezaee</surname><given-names>S</given-names></name></person-group><article-title>Examination of the combined effects of chondroitinase ABC, growth factors and locomotor training following compressive spinal cord injury on neuroanatomical plasticity and kinematics</article-title><source>PLoS One</source><volume>9</volume><fpage>e111072</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0111072</pub-id><pub-id pub-id-type="pmid">25350665</pub-id><pub-id pub-id-type="pmcid">4211738</pub-id></element-citation></ref>
<ref id="b18-mmr-18-01-0025"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janzadeh</surname><given-names>A</given-names></name><name><surname>Sarveazad</surname><given-names>A</given-names></name><name><surname>Yousefifard</surname><given-names>M</given-names></name><name><surname>Dameni</surname><given-names>S</given-names></name><name><surname>Samani</surname><given-names>FS</given-names></name><name><surname>Mokhtarian</surname><given-names>K</given-names></name><name><surname>Nasirinezhad</surname><given-names>F</given-names></name></person-group><article-title>Combine effect of Chondroitinase ABC and low level laser (660 nm) on spinal cord injury model in adult male rats</article-title><source>Neuropeptides</source><volume>65</volume><fpage>90</fpage><lpage>99</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.npep.2017.06.002</pub-id><pub-id pub-id-type="pmid">28716393</pub-id></element-citation></ref>
<ref id="b19-mmr-18-01-0025"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarveazad</surname><given-names>A</given-names></name><name><surname>Babahajian</surname><given-names>A</given-names></name><name><surname>Bakhtiari</surname><given-names>M</given-names></name><name><surname>Soleimani</surname><given-names>M</given-names></name><name><surname>Behnam</surname><given-names>B</given-names></name><name><surname>Yari</surname><given-names>A</given-names></name><name><surname>Akbari</surname><given-names>A</given-names></name><name><surname>Yousefifard</surname><given-names>M</given-names></name><name><surname>Janzadeh</surname><given-names>A</given-names></name><name><surname>Amini</surname><given-names>N</given-names></name><etal/></person-group><article-title>The combined application of human adipose derived stem cells and Chondroitinase ABC in treatment of a spinal cord injury model</article-title><source>Neuropeptides</source><volume>61</volume><fpage>39</fpage><lpage>47</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.npep.2016.07.004</pub-id><pub-id pub-id-type="pmid">27484347</pub-id></element-citation></ref>
<ref id="b20-mmr-18-01-0025"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group><article-title>The combination of db-cAMP and ChABC with poly(propylene carbonate) microfibers promote axonal regenerative sprouting and functional recovery after spinal cord hemisection injury</article-title><source>Biomed Pharmacother</source><volume>86</volume><fpage>354</fpage><lpage>362</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.biopha.2016.12.045</pub-id><pub-id pub-id-type="pmid">28011383</pub-id></element-citation></ref>
<ref id="b21-mmr-18-01-0025"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>ED</given-names></name></person-group><article-title>Inhibition of lipid peroxidation in CNS trauma</article-title><source>J Neurotrauma</source><volume>8</volume><supplement>Suppl 1</supplement><fpage>S31</fpage><lpage>S41</lpage><year>1991</year><pub-id pub-id-type="pmid">1920459</pub-id></element-citation></ref>
<ref id="b22-mmr-18-01-0025"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayan</surname><given-names>K</given-names></name><name><surname>Keser</surname><given-names>A</given-names></name><name><surname>Konyalioglu</surname><given-names>S</given-names></name><name><surname>Erturk</surname><given-names>M</given-names></name><name><surname>Aydin</surname><given-names>F</given-names></name><name><surname>Sengul</surname><given-names>G</given-names></name><name><surname>Dagci</surname><given-names>T</given-names></name></person-group><article-title>The effect of hyperbaric oxygen on neuroregeneration following acute thoracic spinal cord injury</article-title><source>Life Sci</source><volume>90</volume><fpage>360</fpage><lpage>364</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.lfs.2011.12.005</pub-id><pub-id pub-id-type="pmid">22227476</pub-id></element-citation></ref>
<ref id="b23-mmr-18-01-0025"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>CK</given-names></name><name><surname>Cao</surname><given-names>HH</given-names></name><name><surname>Ying</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>HT</given-names></name><name><surname>Yu</surname><given-names>HL</given-names></name></person-group><article-title>The effects of hyperbaric oxygen on macrophage polarization after rat spinal cord injury</article-title><source>Brain Res</source><volume>1606</volume><fpage>68</fpage><lpage>76</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.brainres.2015.01.029</pub-id><pub-id pub-id-type="pmid">25724144</pub-id></element-citation></ref>
<ref id="b24-mmr-18-01-0025"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>CD</given-names></name><name><surname>Zurko</surname><given-names>JC</given-names></name><name><surname>Hanna</surname><given-names>BF</given-names></name><name><surname>Hellenbrand</surname><given-names>DJ</given-names></name><name><surname>Hanna</surname><given-names>A</given-names></name></person-group><article-title>The therapeutic role of interleukin-10 after spinal cord injury</article-title><source>J Neurotrauma</source><volume>30</volume><fpage>1311</fpage><lpage>1324</lpage><year>2013</year><pub-id pub-id-type="doi">10.1089/neu.2012.2651</pub-id><pub-id pub-id-type="pmid">23731227</pub-id></element-citation></ref>
<ref id="b25-mmr-18-01-0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name></person-group><article-title>Further standardization in the aneurysm clip: The effects of occlusal depth on the outcome of spinal cord injury in rats</article-title><source>Spine (Phila Pa 1976)</source><volume>43</volume><fpage>E126</fpage><lpage>E131</lpage><year>2018</year><pub-id pub-id-type="doi">10.1097/BRS.0000000000002279</pub-id><pub-id pub-id-type="pmid">28604493</pub-id></element-citation></ref>
<ref id="b26-mmr-18-01-0025"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>DM</given-names></name><name><surname>Beattie</surname><given-names>MS</given-names></name><name><surname>Bresnahan</surname><given-names>JC</given-names></name></person-group><article-title>A sensitive and reliable locomotor rating scale for open field testing in rats</article-title><source>J Neurotrauma</source><volume>12</volume><fpage>1</fpage><lpage>21</lpage><year>1995</year><pub-id pub-id-type="doi">10.1089/neu.1995.12.1</pub-id><pub-id pub-id-type="pmid">7783230</pub-id></element-citation></ref>
<ref id="b27-mmr-18-01-0025"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>RC</given-names></name><name><surname>Seminerio</surname><given-names>MJ</given-names></name><name><surname>Naser</surname><given-names>ZJ</given-names></name><name><surname>Ford</surname><given-names>JN</given-names></name><name><surname>Martin</surname><given-names>SJ</given-names></name><name><surname>Matsumoto</surname><given-names>RR</given-names></name><name><surname>Rosen</surname><given-names>CL</given-names></name><name><surname>Huber</surname><given-names>JD</given-names></name></person-group><article-title>Effects of aging on behavioral assessment performance: Implications for clinically relevant models of neurological disease</article-title><source>J Neurosurg</source><volume>117</volume><fpage>629</fpage><lpage>637</lpage><year>2012</year><pub-id pub-id-type="doi">10.3171/2012.5.JNS112224</pub-id><pub-id pub-id-type="pmid">22746378</pub-id></element-citation></ref>
<ref id="b28-mmr-18-01-0025"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>J</given-names></name><name><surname>Owada</surname><given-names>K</given-names></name><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Goshima</surname><given-names>Y</given-names></name><name><surname>Ohshima</surname><given-names>T</given-names></name></person-group><article-title>Inhibition of CRMP2 phosphorylation repairs CNS by regulating neurotrophic and inhibitory responses</article-title><source>Exp Neurol</source><volume>277</volume><fpage>283</fpage><lpage>295</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.expneurol.2016.01.015</pub-id><pub-id pub-id-type="pmid">26795088</pub-id></element-citation></ref>
<ref id="b29-mmr-18-01-0025"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nesic</surname><given-names>O</given-names></name><name><surname>Guest</surname><given-names>JD</given-names></name><name><surname>Zivadinovic</surname><given-names>D</given-names></name><name><surname>Narayana</surname><given-names>PA</given-names></name><name><surname>Herrera</surname><given-names>JJ</given-names></name><name><surname>Grill</surname><given-names>RJ</given-names></name><name><surname>Mokkapati</surname><given-names>VU</given-names></name><name><surname>Gelman</surname><given-names>BB</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name></person-group><article-title>Aquaporins in spinal cord injury: The janus face of aquaporin 4</article-title><source>Neuroscience</source><volume>168</volume><fpage>1019</fpage><lpage>1035</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.01.037</pub-id><pub-id pub-id-type="pmid">20109536</pub-id><pub-id pub-id-type="pmcid">2885549</pub-id></element-citation></ref>
<ref id="b30-mmr-18-01-0025"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nesic</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Unabia</surname><given-names>GC</given-names></name><name><surname>Rafati</surname><given-names>D</given-names></name><name><surname>Hulsebosch</surname><given-names>CE</given-names></name><name><surname>Perez-Polo</surname><given-names>JR</given-names></name></person-group><article-title>Acute and chronic changes in aquaporin 4 expression after spinal cord injury</article-title><source>Neuroscience</source><volume>143</volume><fpage>779</fpage><lpage>792</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.08.079</pub-id><pub-id pub-id-type="pmid">17074445</pub-id><pub-id pub-id-type="pmcid">1894918</pub-id></element-citation></ref>
<ref id="b31-mmr-18-01-0025"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shechter</surname><given-names>R</given-names></name><name><surname>Raposo</surname><given-names>C</given-names></name><name><surname>London</surname><given-names>A</given-names></name><name><surname>Sagi</surname><given-names>I</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><article-title>The glial scar-monocyte interplay: A pivotal resolution phase in spinal cord repair</article-title><source>PLoS One</source><volume>6</volume><fpage>e27969</fpage><year>2011</year><pub-id pub-id-type="doi">10.1371/journal.pone.0027969</pub-id><pub-id pub-id-type="pmid">22205935</pub-id><pub-id pub-id-type="pmcid">3244386</pub-id></element-citation></ref>
<ref id="b32-mmr-18-01-0025"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuzzocrea</surname><given-names>S</given-names></name><name><surname>Genovese</surname><given-names>T</given-names></name><name><surname>Mazzon</surname><given-names>E</given-names></name><name><surname>Crisafulli</surname><given-names>C</given-names></name><name><surname>Di Paola</surname><given-names>R</given-names></name><name><surname>Mui&#x00E0;</surname><given-names>C</given-names></name><name><surname>Collin</surname><given-names>M</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name><name><surname>Bramanti</surname><given-names>P</given-names></name><name><surname>Thiemermann</surname><given-names>C</given-names></name></person-group><article-title>Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma</article-title><source>J Pharmacol Exp Ther</source><volume>318</volume><fpage>79</fpage><lpage>89</lpage><year>2006</year><pub-id pub-id-type="doi">10.1124/jpet.106.102863</pub-id><pub-id pub-id-type="pmid">16601144</pub-id></element-citation></ref>
<ref id="b33-mmr-18-01-0025"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Ebong</surname><given-names>EE</given-names></name><name><surname>Fu</surname><given-names>BM</given-names></name><name><surname>Tarbell</surname><given-names>JM</given-names></name></person-group><article-title>The structural stability of the endothelial glycocalyx after enzymatic removal of glycosaminoglycans</article-title><source>PLoS One</source><volume>7</volume><fpage>e43168</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0043168</pub-id><pub-id pub-id-type="pmid">22905223</pub-id><pub-id pub-id-type="pmcid">3419189</pub-id></element-citation></ref>
<ref id="b34-mmr-18-01-0025"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Chu</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>Antisense vimentin cDNA combined with chondroitinase ABC promotes axon regeneration and functional recovery following spinal cord injury in rats</article-title><source>Neurosci Lett</source><volume>590</volume><fpage>74</fpage><lpage>79</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.neulet.2015.01.073</pub-id><pub-id pub-id-type="pmid">25641132</pub-id></element-citation></ref>
<ref id="b35-mmr-18-01-0025"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Sustained delivery of chondroitinase ABC by poly(propylene carbonate)-chitosan micron fibers promotes axon regeneration and functional recovery after spinal cord hemisection</article-title><source>Brain Res</source><volume>1624</volume><fpage>469</fpage><lpage>478</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.brainres.2015.08.018</pub-id><pub-id pub-id-type="pmid">26315376</pub-id></element-citation></ref>
<ref id="b36-mmr-18-01-0025"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Didangelos</surname><given-names>A</given-names></name><name><surname>Iberl</surname><given-names>M</given-names></name><name><surname>Vinsland</surname><given-names>E</given-names></name><name><surname>Bartus</surname><given-names>K</given-names></name><name><surname>Bradbury</surname><given-names>EJ</given-names></name></person-group><article-title>Regulation of IL-10 by chondroitinase ABC promotes a distinct immune response following spinal cord injury</article-title><source>J Neurosci</source><volume>34</volume><fpage>16424</fpage><lpage>16432</lpage><year>2014</year><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2927-14.2014</pub-id><pub-id pub-id-type="pmid">25471580</pub-id><pub-id pub-id-type="pmcid">4252552</pub-id></element-citation></ref>
<ref id="b37-mmr-18-01-0025"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kingwell</surname><given-names>K</given-names></name></person-group><article-title>Spinal cord injury: Clamping down on calpains to treat injury-induced spasticity</article-title><source>Nat Rev Drug Discov</source><volume>15</volume><fpage>310</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/nrd.2016.83</pub-id><pub-id pub-id-type="pmid">27139994</pub-id></element-citation></ref>
<ref id="b38-mmr-18-01-0025"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name></person-group><article-title>Endothelial glycocalyx: Novel insight into atherosclerosis</article-title><source>J Biomed</source><volume>2</volume><fpage>109</fpage><lpage>116</lpage><year>2017</year><pub-id pub-id-type="doi">10.7150/jbm.17725</pub-id></element-citation></ref>
<ref id="b39-mmr-18-01-0025"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name></person-group><article-title>Endothelial glycocalyx as a critical signalling platform integrating the extracellular haemodynamic forces and chemical signalling</article-title><source>J Cell Mol Med</source><volume>21</volume><fpage>1457</fpage><lpage>1462</lpage><year>2017</year><pub-id pub-id-type="doi">10.1111/jcmm.13081</pub-id><pub-id pub-id-type="pmid">28211170</pub-id><pub-id pub-id-type="pmcid">5542909</pub-id></element-citation></ref>
<ref id="b40-mmr-18-01-0025"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwahashi</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><name><surname>Nishimura</surname><given-names>A</given-names></name><name><surname>Ueta</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Shiba</surname><given-names>K</given-names></name></person-group><article-title>Effects of orthotic therapeutic electrical stimulation in the treatment of patients with paresis associated with acute cervical spinal cord injury: A randomized control trial</article-title><source>Spinal Cord</source><month>Jun</month><day>27</day><year>2017</year><comment>(Epub ahead of print)</comment><pub-id pub-id-type="doi">10.1038/sc.2017.74</pub-id><pub-id pub-id-type="pmid">28653674</pub-id></element-citation></ref>
<ref id="b41-mmr-18-01-0025"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shultz</surname><given-names>RB</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name></person-group><article-title>Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury</article-title><source>Neural Regen Res</source><volume>12</volume><fpage>702</fpage><lpage>713</lpage><year>2017</year><pub-id pub-id-type="doi">10.4103/1673-5374.206633</pub-id><pub-id pub-id-type="pmid">28616020</pub-id><pub-id pub-id-type="pmcid">5461601</pub-id></element-citation></ref>
<ref id="b42-mmr-18-01-0025"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera-Aldana</surname><given-names>EE</given-names></name><name><surname>Ruelas</surname><given-names>F</given-names></name><name><surname>Aranda</surname><given-names>C</given-names></name><name><surname>Rincon-Heredia</surname><given-names>R</given-names></name><name><surname>Mart&#x00ED;nez-Cruz</surname><given-names>A</given-names></name><name><surname>Reyes-S&#x00E1;nchez</surname><given-names>A</given-names></name><name><surname>Guizar-Sahag&#x00FA;n</surname><given-names>G</given-names></name><name><surname>Tovar-Y-Romo</surname><given-names>LB</given-names></name></person-group><article-title>Methylprednisolone administration following spinal cord injury reduces aquaporin 4 expression and exacerbates edema</article-title><source>Mediators Inflamm</source><volume>2017</volume><fpage>4792932</fpage><year>2017</year><pub-id pub-id-type="doi">10.1155/2017/4792932</pub-id><pub-id pub-id-type="pmid">28572712</pub-id><pub-id pub-id-type="pmcid">5442433</pub-id></element-citation></ref>
<ref id="b43-mmr-18-01-0025"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatar</surname><given-names>S</given-names></name><name><surname>Orhan</surname><given-names>N</given-names></name><name><surname>Yilmaz</surname><given-names>CU</given-names></name><name><surname>Arican</surname><given-names>N</given-names></name><name><surname>Ahishali</surname><given-names>B</given-names></name><name><surname>Kucuk</surname><given-names>M</given-names></name><name><surname>Elmas</surname><given-names>I</given-names></name><name><surname>Kaya</surname><given-names>M</given-names></name><name><surname>Toklu</surname><given-names>AS</given-names></name></person-group><article-title>Hyperbaric oxygen therapy for five days increases blood-brain barrier permeability</article-title><source>Undersea Hyperb Med</source><volume>44</volume><fpage>345</fpage><lpage>355</lpage><year>2017</year><pub-id pub-id-type="doi">10.22462/7.8.2017.7</pub-id><pub-id pub-id-type="pmid">28783891</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-18-01-0025" position="float">
<label>Figure 1.</label>
<caption><p>Effect of HBO, chondroitinase ABC enzyme or combined HBO and enzyme treatment on the recovery of locomotor activity following SCI. Recovery of locomotor activity was assessed by the BBB scale. Data is expressed as the mean &#x00B1; standard error. &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. SCI; <sup>##</sup>P&#x003C;0.01, <sup>###</sup>P&#x003C;0.001 vs. HBO; <sup>&#x0026;&#x0026;</sup>P&#x003C;0.01, <sup>&#x0026;&#x0026;&#x0026;</sup>P&#x003C;0.001 vs. enzyme group. SCI, spinal cord injury; HBO, hyperbaric oxygen; BBB, Basso-Beattie-Bresnahan.</p></caption>
<graphic xlink:href="MMR-18-01-0025-g00.tif"/>
</fig>
<fig id="f2-mmr-18-01-0025" position="float">
<label>Figure 2.</label>
<caption><p>Effect of HBO, chondroitinase ABC enzyme or HBO and enzyme treatment on the maximum inclined plane angle following SCI. Data is expressed as the mean &#x00B1; standard error. &#x002A;&#x002A;P&#x003C;0.01 vs. SCI; <sup>#</sup>P&#x003C;0.05 vs. HBO group; <sup>&#x0026;</sup>P&#x003C;0.05 vs. enzyme group. HBO, hyperbaric oxygen; SCI, spinal cord injury.</p></caption>
<graphic xlink:href="MMR-18-01-0025-g01.tif"/>
</fig>
<fig id="f3-mmr-18-01-0025" position="float">
<label>Figure 3.</label>
<caption><p>SOD and MDA levels of rats pre- and post-SCI establishment. (A) SOD levels were detected by xanthine oxidase assay. (B) MDA levels were detected by thiobarbituric acid. &#x002A;P&#x003C;0.05 vs. Sham; <sup>#</sup>P&#x003C;0.05 vs. SCI group; <sup>&#x0026;</sup>P&#x003C;0.05 vs. HBO group; <sup>@</sup>P&#x003C;0.05 vs. enzyme group. SOD, superoxide dismutase; MDA, malondialdehyde; SCI, spinal cord injury; HBO, hyperbaric oxygen.</p></caption>
<graphic xlink:href="MMR-18-01-0025-g02.tif"/>
</fig>
<fig id="f4-mmr-18-01-0025" position="float">
<label>Figure 4.</label>
<caption><p>Effect of HBO, chondroitinase ABC enzyme or combined HBO and enzyme treatment on GSK3&#x03B2; expression in SCI rats 4 weeks following surgery. GSK3&#x03B2; protein expression was determined by western blot analysis and normalized to GAPDH. Data is expressed as the mean &#x00B1; standard error. &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. control group; <sup>##</sup>P&#x003C;0.01, <sup>###</sup>P&#x003C;0.001 vs. SCI group. HBO, hyperbaric oxygen; GSK3&#x03B2;, glycogen synthase kinase-3&#x03B2;; SCI, spinal cord injury.</p></caption>
<graphic xlink:href="MMR-18-01-0025-g03.tif"/>
</fig>
<fig id="f5-mmr-18-01-0025" position="float">
<label>Figure 5.</label>
<caption><p>Effect of HBO, chondroitinase ABC enzyme or combined HBO and enzyme treatment on AQP4 expression in SCI rats 4 weeks following surgery. AQP4 protein expression was determined by western blot analysis and normalized to GAPDH. Data is expressed as the mean &#x00B1; standard error. &#x002A;&#x002A;P&#x003C;0.001 vs. control group; <sup>##</sup>P&#x003C;0.01, <sup>###</sup>P&#x003C;0.001 vs. SCI group. HBO, hyperbaric oxygen; AQP4, aquaporin 4; SCI, spinal cord injury.</p></caption>
<graphic xlink:href="MMR-18-01-0025-g04.tif"/>
</fig>
<table-wrap id="tI-mmr-18-01-0025" position="float">
<label>Table I.</label>
<caption><p>Experimental groups.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Experimental groups (n=8)</th>
<th align="center" valign="bottom">Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">Animals were surgically exposed and treated with regular air, however not subjected to the SCI procedure.</td>
</tr>
<tr>
<td align="left" valign="top">SCI</td>
<td align="left" valign="top">Animals with SCI treated with regular air (no treatment).</td>
</tr>
<tr>
<td align="left" valign="top">Vehicle</td>
<td align="left" valign="top">Animals with SCI that received 10 &#x00B5;l buffer phosphate saline injection and treated with regular air (intra-spinal)</td>
</tr>
<tr>
<td align="left" valign="top">HBO</td>
<td align="left" valign="top">Animals with SCI treated by HBO (80&#x0025; oxygen at 0.3 MPa)</td>
</tr>
<tr>
<td align="left" valign="top">Enzyme</td>
<td align="left" valign="top">Animals with SCI that received 10 &#x00B5;l of 100 U/ml of chondroitinase ABC injection and treated with regular air (intra spinal)</td>
</tr>
<tr>
<td align="left" valign="top">HBO &#x002B; enzyme</td>
<td align="left" valign="top">Animals with spinal cord injury treated with HBO and chondroitinase ABC</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-mmr-18-01-0025"><p>SCI, spinal cord injury; HBO, hyperbaric oxygen.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>